Sensitive, single‑cell immune readouts for decision‑ready data

ELISpot directly quantifies antibody‑ or cytokine‑secreting cells, making it a gold‑standard tool to characterize antigen‑specific T‑ and B‑cell responses in regulated studies.

specific-cytokine-receptors-on-the-target-cell-surface

Choose Eurofins BioPharma Services for your ELISpot assay

  • Regulated, reliable, reproducible. Your studies run within GLP/GCP‑aligned quality systems in our purpose‑built Lenexa facility—engineered for data integrity and audit readiness. 

  • Validation you can defend. Our processes reflect Global CRO Council recommendations for ELISpot validation, including appropriate controls and performance criteria, and we apply published specificity best practices (assay, donor, antigen) to de‑risk interpretation. 

  • End‑to‑end sample chain. Integrated PBMC isolation, cryopreservation, storage, and shipping protect cell function and consistency from site to readout. 

  • Built to scale. We offer ELISpot and FluoroSpot for multiplex single‑cell detection—expanding biomarker breadth without sacrificing sensitivity or turnaround.

What we offer

  • T‑ & B‑cell ELISpot to quantify antigen‑specific cytokine or antibody secretion for immunogenicity and functional response assessments.

  • Neutralizing antibody (NAb) contexts, where ELISpot‑based readouts complement ligand‑binding or cell‑based methods. 

  • FluoroSpot multiplexing when two markers must be measured simultaneously at the single‑cell level.

photomicrograph-of-diffuse-large-b-cell-lymphoma-testicular-biopsy-showing-prominent-nucleoli
vaccines-vaccination-has-been-one-of-the-most-important-medical-achievements-in-human-history-preventing-the-spread-of-infectious-diseases-such-as-smallpox-polio

Where ELISpot fits best

  • Vaccine development: quantify cellular immunogenicity and memory responses alongside serology and flow‑based phenotyping.

  • Cell therapy: track cellular activation and functionality in CAR‑T and adoptive cell programs, integrated with spectral flow and qPCR kinetics.

  • Infectious disease trials: measure pathogen‑specific T‑cell function as a complement to molecular and serologic endpoints.